At NeoPharm, the Buck Stops Before Kapoor
Kapoor wants shareholders to remove directors Sander Flaum, Erick Hanson (who replaced Kapoor as chairman), Matthew Rogan and Kaveh Safavi -- each of whom is deemed independent, according to the company.
In their place, Kapoor has nominated three new directors -- Brian Tambi, Ronald Eidell and Bernard Fox. Kapoor and current CEO Greg Young would remain directors.
As noted above, given the sorry state of NeoPharm these days, investors seem justified in questioning the competence of the current board. But it seems disingenuous for Kapoor to say that, somehow, he hasn't also been responsible for the company's many screwups. He is a founder and the largest shareholder, after all, and served as the company's chairman.
Kapoor could not be reached for comment. But his spokesman Michael Babich says Kapoor, as chairman, tried to take the company in another direction, but was often overruled by the other directors. Kapoor "has been chairman, but that did not give him the authority to overrule the board. His vote counts only once, just like the other directors," Babich said, adding that "this is why Kapoor is being forced to take this action."Kapoor's slate of chosen directors does not appear to be entirely independent. Tambi is currently CEO and chairman of privately held Morton Grove Pharmaceuticals. But from 1986 to 1990, Tambi worked for Kapoor at Lyphomed, which Kapoor eventually sold to Japanese drugmaker Fujisawa. (Tambi stayed on at Fujisawa for another two years.) After the deal closed, Fujisawa sued Kapoor for fraud under the federal civil racketeering statute; the case was eventually settled in 1999 under confidential terms. A second Kapoor nominee, Bernard Fox, has also served as a consultant to the company. And under Kapoor's previous leadership as chairman, NeoPharm has fallen far short of good corporate governance practices. The SEC first informed NeoPharm that it was under investigation in March, but this fact
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV